Actively Recruiting

Age: 19Years +
All Genders
ID07374679

Long-Term Follow-Up Study to Evaluate Safety and Efficacy of Allogenic Umbilical Cord-derived Mesenchymal Stem Cells in Rotator Cuff Disease

Led by Seoul National University Hospital · Updated on 2026-05-22

21

Participants Needed

1

Research Sites

35 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to evaluate the long-term safety and effectiveness of allogenic umbilical cord-derived mesenchymal stem cells in patients with rotator cuff disease. The study focuses on monitoring outcomes decades after initial treatment to understand the lasting impact of this therapy. Participants are those who previously received this investigational stem cell treatment in an earlier phase 1/2a trial. This open-label, single-center study involves a long-term follow-up period extending up to 60 months where patients are observed and evaluated without additional new treatments being administered. During the follow-up, researchers will assess shoulder pain and disability using the Shoulder Pain and Disability Index (SPADI) score and other measures like the Constant-Murley score and Visual Analog Scale pain during motion. Imaging tests such as MRI will monitor changes in rotator cuff tear size, and any adverse events will be recorded. Participation involves periodic assessments over a five-year period ending in 2032, with safety and efficacy carefully tracked.

CONDITIONS

Brief Title

Long-Term Follow-up Study to Evaluate Long-Term Safety and Efficacy of Allogenic Umbilical Cord-derived Mesenchymal Stem Cell in Patients With Rotator Cuff Disease

Who Can Participate

Age: 19Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Received the investigational medicinal product in the Phase 1/2a clinical trial (ASB-IP-001)
  • Voluntarily agreed to participate in this long-term follow-up study and provided written informed consent
Not Eligible

You will not qualify if you...

  • Cannot be contacted by telephone, mail, or e-mail, making follow-up assessment impossible
  • Deemed inappropriate for participation by the investigator, including cases posing significant health or safety risk
  • Cases where follow-up visits or assessments are practically impossible due to cognitive impairment or communication difficulties
  • Cases unlikely to continue follow-up due to difficulty adhering to the study schedule (e.g., prolonged hospitalization, long-term residence abroad)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Long-term Monitoring

Duration - Up to 60 months

Participants who previously received the investigational product are followed over time to assess long-term safety and efficacy.

Visits scheduled over 60 months for follow-up assessments

Trial Site Locations

Total: 1 location

1

Joint & Spine Center, SMG-SNU Boramae Medical Center, Department of Orthopedic Surgery, Seoul National University College of Medicine

Seoul, Korea, South Korea, 07061

Actively Recruiting

Loading map...

Research Team

K

KeeJeong Bae, Principal Investigator

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Arthroscopic Rotator Cuff Repair with Umbilical Cord-derived...

Rotator Cuff Disease

Actively Recruiting

1 location

Safety and Exploratory Efficacy of Allogenic Umbilical Cord-...

Rotator Cuff Disease

Actively Recruiting

1 location

Establishing the Clinical Significance Values of Scales Used...

Rotator Cuff Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here